Construction and Validation of a Novel Immunosignature for Overall Survival in Uveal Melanoma

Chufeng Gu1,2†, Xin Gu3†, Yujie Wang1,2†, Zhixian Yao4* and Chuandi Zhou1,2*

1 Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 National Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China, 3 Department of Ophthalmology, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China, 4 Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Objectives: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and immune infiltration plays a crucial role in the prognosis of UM. This study aimed to generate an immunological marker-based predictive signature for the overall survival (OS) of UM patients.

Methods: Single-sample gene-set enrichment analysis (ssGSEA) was used to profile immune cell infiltration in 79 patients with UM from The Cancer Genome Atlas (TCGA) database. Univariate and multivariate least absolute shrinkage and selection operator (LASSO) Cox regressions were used to determine the prognostic factors for UM and construct the predictive immunosignature. Receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration curves were performed to evaluate the clinical ability and accuracy of the model. In addition, the predictive accuracy was compared between the immunosignature and the Tumor, Node, Metastasis (TNM) staging system of American Joint Committee on Cancer (AJCC). We further analyzed the differences in clinical characteristics, immune infiltrates, immune checkpoints, and therapy sensitivity between high- and low-risk groups characterized by the prognostic model.

Results: Higher levels of immune cell infiltration in UM were related to a lower survival rate. Matrix metalloproteinase 12 (MMP12), TCDD inducible poly (ADP-ribose) polymerase (TIPARP), and leucine rich repeat neuronal 3 (LRRN3) were identified as prognostic signatures, and an immunological marker-based prognostic signature was constructed with good clinical ability and accuracy. The immunosignature was developed with a concordance index (C-index) of 0.881, which is significantly better than that of the TNM staging system (p < 0.001). We further identified 1,762 genes with upregulated expression and 798 genes with downregulated expression in the high-risk group, and the differences between the high- and low-risk groups were mainly in immune-related processes. In addition, the expression of most of the immune
checkpoint-relevant and immune activity-relevant genes was significantly higher in the high-risk group, which was more sensitive to therapy.

**Conclusion:** We developed a novel immunosignature constructed by MMP12, TIPARP, and LRRN3 that could effectively predict the OS of UM.

**Keywords:** uveal melanoma, immune microenvironment, immunological marker, overall survival, prognostic signatures

**BACKGROUND**

Uveal melanoma (UM), arising from melanocytes in the uvea, is the most common primary intraocular malignancy in adults (Li et al., 2020). More than 90% of UM cases have choroidal involvement, and the remaining 10% are confined to the ciliary body or the iris (Shields et al., 2012). Genetic mutations in G protein subunit alpha q (GNAQ) and G protein subunit alpha 11 (GNAI1) are suspected to be the initiating event in UM (Vader et al., 2017). Despite the advancements in diagnostics and therapies for UM, the prognosis of patients with UM remains unsatisfactory (Kashyap et al., 2016; Rantala et al., 2019). Almost 50% of UM patients develop metastasis and have an overall survival (OS) of less than 1 year (Kujala et al., 2003; Jager et al., 2020). Therefore, identifying high-risk patients at the initial diagnosis is of great importance and may guide clinicians in their therapeutic decisions.

The pathogenetic mechanisms and markers that influence the prognosis of UM patients have been extensively investigated in the past few decades (Li et al., 2020). Accumulating evidence reveals that chromosomal abnormalities in UM, including chromosome 3 monosomy (monosomy 3), gains of chromosomal arm 8q, and loss of chromosomal arm 1p, are closely related to an increased risk of metastasis (Aalto et al., 2001; Trolet et al., 2009; Damato et al., 2010), while gain of chromosomal arm 6p is associated with longer metastasis-free survival (MFS; Aalto et al., 2001). In addition, the genetic mutation of BRCA1-associated protein 1 (BAP1) was associated with higher chances of metastasis (Kalirai et al., 2014), while an alteration in splicing transcription factor 2 (TBX2) and tumor necrosis factor (TNF) 2,3-dioxygenase (IDO), and lymphocyte-activation gene 3 (LAG3) as immune checkpoint-relevant signatures and CD8 antigen (CD8A), C-X-C motif chemokine ligand 10 (CXCL10), cytokotoxic T-lymphocyte associated protein 4 (CTLA4), T-cell immunoglobulin mucin family member 3 (TIM3), indoleamine 2,3-dioxygenase (IDO), and lymphocyte-activation gene 3 (LAG3) as immune checkpoint-relevant signatures and CD8 antigen (CD8A), C-X-C motif chemokine ligand 10 (CXCL10), CXCL9, granzyme A (GZMA), GZMB, perforin 1 (PRF1), T-box transcription factor 2 (TBX2), and tumor necrosis factor (TNF) as immune activity-related signatures (Zhang et al., 2020).

**Survival Analysis**

Kaplan–Meier survival curves were drawn using the “survival” package in R 3.5.1 to analyze the survival differences between

---

1. https://portal.gdc.cancer.gov/projects/TCGA-UVM

2. https://www.ncbi.nlm.nih.gov/geo/
subgroups, and the major outcome is OS, and the secondary outcome is progress-free survival (PFS). Metastasis, and tumor-related death were modeled as major outcomes (dependent factors), and patients who were alive at the end of follow-up or who died of other causes were considered censored. The survival proportions of subgroups were compared using a two-sided log-rank test.

**Prognostic Model Construction and Validation**

To identify the possible correlates of the OS, 484 immunological markers of 24 immune cell types were compared using univariate Cox proportional hazards regressions. The significant factors were further applied to least absolute shrinkage and selection operator (LASSO) Cox regression analysis. The LASSO regression model analysis was performed using “glmnet” package in R 3.5.1, and non-zero coefficients and minimum of lambda were used for gene cut-off. The risk scores were estimated from the coefficients of the genes, which were calculated in accordance with the highest lambda value. Patients were stratified into the high-risk or low-risk group according to the median value of the risk score.

Receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were performed to assess the clinical usefulness of the prognostic model on survival probability using the “survivalROC” and “ggDCA” packages in R 3.5.1. Higher values of area under curve (AUC) indicated better classification ability. Calibration curves of the prognostic model for the OS were examined to assess the agreement between the predicted and observed outcomes. The concordance index (C-index) of the immunosignature and the Tumor, Node, Metastasis (TNM) staging system of American Joint Committee on Cancer (AJCC) were compared using “CsChange” package in R 3.5.1.

**Functional Enrichment Analysis**

Differentially expressed genes (DEGs) between the high- and low-risk groups were identified with \( \log_2 \) (fold change) \( > 1.5 \) and adjusted \( p \)-value \( < 0.05 \). Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the high- and low-risk groups were performed using the “clusterprofiler” package in R 3.5.1. Gene set enrichment analysis (GSEA) was assessed the differences in signaling pathways between the high- and low-risk groups to predict the phenotypes and signaling pathways related to prognosis. The “clusterprofiler” package implements a hypergeometric test for each pathway and returns a \( p \)-value. A cutoff of 0.05 was used to identify enriched pathways. And the adjusted \( p \)-value was generated by the Bonferroni correction (“Bonferroni”) in which the \( p \)-values are multiplied by the number of comparisons (Benjamini and Hochberg, 1995).

**Therapeutic Sensitivity Prediction**

To explore the sensitivity of therapy in the high- and low-risk groups, we predicted the drug sensitivity using the Genomics of Drug Sensitivity in Cancer (GDSC) database\(^1\) (Yang et al., 2013).

The prediction process was implemented using the “pRRophetic” package to estimate the half maximal inhibitory concentration (IC50) of drugs by ridge regression and the prediction accuracy was evaluated by 10-fold cross-validation based on the GDSC training set (Geeleher et al., 2014).

**Statistical Analysis**

All statistical analyses were performed in R 3.5.1. Mean \( \pm \) standard deviation (SD) and frequency (percentage) were reported for the description of categorical variables and continuous variables. Means and proportions were compared using Student’s \( t \)-test, the non-parametric Mann–Whitney \( U \) test and the chi-square test (or Fisher’s exact test, if appropriate), respectively. Univariate Cox regression and LASSO Cox regression were used to determine the significant factors, and hazard ratios with 95% confidence interval (CI) were recorded. The survival and metastasis rates of subgroups were compared using a log-rank test. The comparison between immunosignature and TNM staging system was evaluated by C-index. A model with a larger C-index was considered to have a greater discrimination ability. All statistical tests were two sided, and \( p < 0.05 \) was considered statistically significant.

**RESULTS**

**Identification of Prognostic Signature in UM**

We used ssGSEA to quantify 24 immune cell types in the TCGA cohort and noted heterogeneity in the infiltration of immune cell types in UM patients (Figure 1A). Through hierarchical clustering, we found two distinct groups with different immune infiltration patterns. Mutation status of GNAQ, GNA11, SF3B1, and BAP1, sex, survival, and clinical stage are annotated in the lower panel (Figure 1A). Further, the Kaplan–Meier curve showed that the cumulative survival rate of patients with high infiltration status was significantly lower than that of patients in the low infiltration group (\( p = 0.024 \), Figure 1B). Similarly, this phenomenon was further validated in the GSE44295 cohort: infiltration heterogeneity also appeared in UM patients (Figure 1C), and patients with high infiltration status showed lower OS (\( p = 0.047 \), Figure 1D).

To further investigate the immune-related biomarkers that could predict the prognosis of UM, univariate Cox regression and LASSO Cox regression were used to analyze the roles of 484 immunological markers of 24 immune cells. After univariate Cox regression analyses, 219 factors were further analyzed by LASSO Cox regression. After 10-fold cross-validation, we used non-zero coefficients for gene cut-off and the minimum criteria for lambda was 0.17646, which is the value of lambda that gives the most regularized model such that the cross-validated error is within one standard error of the minimum (Figures 2A,B and Supplementary Figure 1). Three genes were identified: matrix metallopeptidase 12 (MMP12), TCDD inducible poly (ADP-ribose) polymerase (TIPARP), and leucine rich repeat neuronal 3 (LRRN3). The hazard ratio of MMP12, TIPARP, and LRRN3 was 1.23 (95% CI, 1.1–1.37), 0.26 (95% CI, 0.1–0.65),

---

\(^1\)https://www.cancerrxgene.org
Immune landscape of uveal melanoma (UM). (A) Unsupervised clustering was applied to 79 UM patients from the The Cancer Genome Atlas (TCGA) database using the single-sample gene-set enrichment analysis (ssGSEA) scores of 24 immune cell types. Mutation status of G protein subunit alpha q (GNAQ), G protein subunit alpha 11 (GNA11), splicing factor 3b subunit 1 (SF3B1), and BRCA1-associated protein 1 (BAP1), sex, survival, and stage are annotated in the lower panel. (B) Kaplan–Meier curves for the overall survival (OS) of UM patients in the TCGA dataset grouped by high and low infiltration levels. (C) Unsupervised clustering was applied to 57 UM patients from the GSE44295 dataset using the ssGSEA scores of 24 immune cell types. Metastatic status, sex, and survival are annotated in the lower panel. (D) Kaplan–Meier curves for the OS of UM patients in the GSE44295 dataset grouped by high and low infiltration levels.

and 1.47 (95% CI, 1.1–1.94), respectively (Figure 2C). Then, we constructed a risk signature based on the expression of specific genes [transcripts per kilobase of exon model per million mapped reads (TPM)] and the coefficients from the Cox regression. The risk score formula was calculated as follows:

\[
\text{Risk score} = 0.20332 \times (\text{TPM of MMP12}) - 1.36517 \\
\times (\text{TPM of TIPARP}) + 0.38766 \times (\text{TPM of LRRN3})
\]

To explore the optimal cutoff value that could be used to stratify patients into the high- and low-risk groups, the time-dependent ROC curve analysis was used, and the optimal cutoff value was determined to be 0.43 (Figure 2D). The heat map showed the expression level of the three genes in each UM patient (Figure 2D). We further investigate the prognosis of patients in high- and low-risk groups characterized by the prognostic model. Kaplan–Meier curves revealed that patients in the high-risk group had lower OS \((p < 0.001, \text{Figure 2E})\) and PFS \((p < 0.001, \text{Figure 2F})\) than patients in the low-risk group.

**Validation of Prognostic Signature in UM**

To assess the clinical usefulness of the prognostic model on the survival probability of UM patients, ROC, calibration plots, and DCA curves were performed. The AUC values for the 1- and 3-year OS in the TCGA dataset were 0.869 (95% CI, 0.767–0.971) and 0.911 (95% CI, 0.827–0.995), respectively (Figure 3A). The calibration plots displayed fair agreement between the predictions and actual observations for the 1- and 3-year OS in the TCGA dataset (Figure 3B), and the DCA showed that using the prognostic signature to predict the OS had more
FIGURE 2 | Identification of an optimal marker model for prognostic prediction in the TCGA dataset UM patients. (A) 10-fold cross-validation for tuning parameter selection in the least absolute shrinkage and selection operator (LASSO) model. The first vertical line equals the minimum error (lambda = 0.05265), whereas the second vertical line shows the cross-validated error within one standard error of the minimum (lambda = 0.17646). (B) LASSO coefficient profiles of the fractions of 219 immune cell markers. Each curve corresponds to a variable. It shows the path of its coefficient against the L1-Norm of the whole coefficient vector as lambda varies. The axis above indicates the number of non-zero coefficients at the current lambda, which is the effective degrees of freedom (df) for the LASSO. (C) Forest plots showing associations between different immune cell markers and OS in the TCGA cohort. Unadjusted hazard ratios are shown with 95% confidence interval (CI). (D) Characteristics of the 3-gene pair prognostic signature. (top): the risk score of each UM patient; (middle): OS and survival status of UM patients; (bottom): heat map of gene expression profiles of UM patients in the TCGA cohort. (E) Kaplan–Meier curves for the OS of UM patients in high- and low-risk groups. (F) Kaplan–Meier curves for the progress-free survival (PFS) of UM patients in high- and low-risk groups.
benefit than either the “treat-all” model or the “treat-none” model for most of patients in the TCGA dataset (Figure 3C). In the GSE44295 validation dataset, AUC values of 0.917 (95% CI, 0.827–1.000) and 0.734 (95% CI, 0.592–0.877) were obtained for the 1— and 3-year OS, respectively (Figure 3D). The calibration plots displayed favorable agreement between the predictions and actual observations (Figure 3E), and the DCA showed that using the prognostic signature to predict the OS was more beneficial for most of patients in the GSE44295 dataset (Figure 3F). The prognostic signature has also been proven effective in the GSE22138 validation dataset (Supplementary Figure 2).

We further compared the accuracy of the immuno-signature with the conventional TNM staging system. The immuno-signature has a more stable discrimination ability than TNM staging system (Supplementary Figure 3). The C-index of the immuno-signature was 0.881 (95% CI, 0.823–0.939), whereas for TNM staging, the C-index was limited to 0.619 (95% CI, 0.482–0.756). The details of the comparisons are summarized in Table 1.

### The Comparisons of Clinical and Pathologic Characteristics of Patients Between High- and Low-Risk Groups

Furthermore, we investigated the clinical and pathologic characteristics of patients in high- and low-risk groups. There were no significant differences in age ($p = 0.148$) or sex ($p = 1.000$) between the high- and low-risk groups. More than half of the patients in the high-risk group were in stage III or IV, while 60% of the patients in the low-risk group were in stage II ($p = 0.038$). Moreover, in terms of histological type, patients in the high-risk group mainly had more epithelioid cell type than those in the low-risk group ($p = 0.011$). In addition, the status of chromosomes 3, 8q, 6p, and 1p in the different subgroups was assessed. The proportion of monosomy 3 accounted for 85% in the high-risk group but only 12% in the low-risk group ($p < 0.001$). The gains of 8q and 6p were 79 and 26%, respectively, in the high-risk group, while the proportions in the low-risk group were 35 and 78% (all $p < 0.001$). Furthermore, the mutation status of SF3B1, BAP1, GNAQ, and GNA11 in the different risk subgroups was assessed. The mutation of SF3B1 was significantly higher in the low-risk group ($p = 0.004$). The

### Table 1: The Comparison of Predictive Discrimination Ability of the Immuno-signature and Tumor, Node, Metastasis (TNM) Staging System

| Comparison of models | C-index (95% CI) | $p$-value |
|----------------------|-----------------|-----------|
| Immunosignature      | 0.881 (0.823, 0.939) | $< 0.001^*$ |
| T stage              | 0.619 (0.482, 0.756) | $< 0.001^*$ |

$^*$Statistically significant.
TABLE 2 | Clinical and pathologic characteristics of patients in the high- and low-risk groups.

| Variables                  | Total (n = 79) | High risk (n = 39) | Low risk (n = 40) | p-value |
|---------------------------|---------------|-------------------|------------------|---------|
| Age (years)               | 61.47 ± 13.94 | 63.77 ± 13.11     | 59.23 ± 14.52    | 0.148   |
| Gender                    |               |                   |                  | 1.000   |
| Female                    | 35 (44%)      | 17 (44%)          | 18 (45%)         |         |
| Male                      | 44 (56%)      | 22 (56%)          | 22 (55%)         |         |
| T Stage                   |               |                   |                  | 0.038*  |
| Stage II                  | 39 (49%)      | 15 (38%)          | 24 (60%)         |         |
| Stage III                 | 35 (44%)      | 19 (49%)          | 16 (40%)         |         |
| Stage IV                  | 4 (5%)        | 4 (10%)           | 0 (0%)           |         |
| Missing                   | 1 (1%)        | 1 (3%)            | 0 (0%)           |         |
| Histological type         |               |                   |                  | 0.011*  |
| Epithelioid cell type     | 13 (16%)      | 10 (26%)          | 3 (8%)           |         |
| Spindle cell type         | 30 (38%)      | 9 (23%)           | 21 (52%)         |         |
| Mixed cell type           | 36 (46%)      | 20 (51%)          | 16 (40%)         |         |
| Chromosome 3 status       |               |                   |                  | < 0.001*|
| Monosomy 3                | 38 (48%)      | 33 (85%)          | 5 (12%)          |         |
| Disomy 3                  | 39 (49%)      | 5 (13%)           | 34 (85%)         |         |
| Missing                   | 2 (3%)        | 1 (3%)            | 1 (2%)           |         |
| Chromosome 8q status      |               |                   |                  | < 0.001*|
| Gained                    | 45 (57%)      | 31 (79%)          | 14 (35%)         |         |
| Not called                | 21 (27%)      | 5 (13%)           | 16 (40%)         |         |
| Missing                   | 13 (16%)      | 3 (8%)            | 10 (25%)         |         |
| Chromosome 6p status      |               |                   |                  | < 0.001*|
| Gained                    | 41 (52%)      | 10 (26%)          | 31 (78%)         |         |
| Not called                | 36 (46%)      | 28 (72%)          | 8 (20%)          |         |
| Missing                   | 2 (3%)        | 1 (3%)            | 1 (2%)           |         |
| Chromosome 1p status      |               |                   |                  | 0.184   |
| Lost                      | 17 (22%)      | 11 (28%)          | 6 (15%)          |         |
| Not called                | 57 (72%)      | 27 (69%)          | 30 (75%)         |         |
| Missing                   | 5 (6%)        | 1 (3%)            | 4 (10%)          |         |
| SF3B1 status              |               |                   |                  | 0.004*  |
| Mutant                    | 18 (23%)      | 3 (8%)            | 15 (38%)         |         |
| Wild type                 | 61 (77%)      | 36 (92%)          | 25 (62%)         |         |
| BAP1 status               |               |                   |                  | 0.076   |
| Mutant                    | 15 (19%)      | 11 (28%)          | 4 (10%)          |         |
| Wild type                 | 64 (81%)      | 28 (72%)          | 36 (90%)         |         |
| GNAQ status               |               |                   |                  | 0.055   |
| Mutant                    | 38 (48%)      | 14 (36%)          | 24 (60%)         |         |
| Wild type                 | 41 (52%)      | 25 (64%)          | 16 (40%)         |         |
| GNA11 status              |               |                   |                  | 0.056   |
| Mutant                    | 35 (44%)      | 22 (56%)          | 13 (32%)         |         |
| Wild type                 | 44 (56%)      | 17 (44%)          | 27 (68%)         |         |

1. Tumor category according to 8th edition of American Joint Committee on Cancer (AJCC) staging system; SF3B1, splicing factor 3b subunit 1; BAP1, BRCA1-associated protein 1; GNAQ, G protein subunit alpha q; GNA11, G protein subunit alpha 11.

Data are presented as mean ± standard deviation (SD)/n (%). *Statistically significant.

clinical and pathologic characteristics of patients are detailed in Table 2.

Functional Annotation Between High- and Low-Risk Groups of UM Patients

To explore the underlying biological mechanisms of distinct immunophenotypes, we performed differential and functional analyses to identify DEGs and pathways between the high- and low-risk groups. The result of principal component analysis (PCA) was consistent with the risk classification (Figure 4A). We identified 1,762 genes with upregulated expression and 798 genes with downregulated expression in the high-risk group (Figure 4B and Supplementary Table 1). And GO analysis, including biological process (BP), cellular component (CC), and molecular function (MF), and KEGG functional enrichment analysis were further performed. The GO analysis revealed that the DEGs were mostly enriched in immune responses, such as
FIGURE 4 | Functional enrichment analysis between high- and low-risk UM groups. (A) principal component analysis (PCA) successfully separated the high- and low-risk UM patients. (B) Volcano plot displaying the differentially expressed genes (DEGs) between the high- and low-risk groups. The log2 (fold change) of TCDD inducible poly (ADP-ribose) polymerase (TIPARP), leucine rich repeat neuronal 3 (LRRN3), and matrix metallopeptidase 12 (MMP12) was –1.46, 2.46, and 5.86, respectively. (C) Gene ontology (GO). (D) Kyoto Encyclopedia of Genes and Genomes (KEGG), and (E,F) Gene set enrichment analysis (GSEA) analyses compared the difference between the high- and low-risk UM groups.
the humoral immune response, lymphocyte mediated immunity, and the T cell receptor complex (Figure 4C). Moreover, KEGG analysis also revealed that DEGs were significantly enriched in immunity-related pathways (Figure 4D), such as Cytokine–cytokine receptor interaction, Graft-versus-host disease, and Allograft rejection (Supplementary Figure 4). A detailed table of KEGG terms is provided in Supplementary Table 2. Besides, GSEA analysis also revealed that the DEGs were mostly enriched in immune responses, including Allograft rejection, Asthma, and Intestinal immune network for IgA production (Figures 4E,F).

To further analyze the immune activity and tolerance condition of each group, the variations of immune cells and checkpoints between the high- and low-risk groups were investigated. In general, the degree of cell infiltration was lower in the low-risk group than in the high-risk group, except for eosinophils and T helper 17 (Th17) cells (Figure 5A). In addition, we found that most of the immune checkpoint-relevant and immune activity-relevant genes were significantly higher in the high-risk group, except for TBX2 (Figure 5B).

**High-Risk Group Was MoreSensitive to Therapy**

To explore the differences of drug sensitivity between the high- and low-risk groups, we used GDSC database to estimate the IC50 of drugs. Twelve therapeutic drugs were identified,
including BMS-536924, PF4708671, Sunitinib, MK2206, Gefitinib, Lapatinib, Parthenolide, Motesanib, PLX4720, BMS754807, Sorafenib, and MS-275, as the estimated IC50 of these chemotherapeutic drugs were lower in the high-risk group than those in the low-risk group (Figure 6).

DISCUSSION

In the present study, we initially identified MMP12, TIPARP, and LRRN3 as crucial immunological markers related to the prognosis of UM and generated an immunological marker-based predictive signature for UM patients. MMP12 is one of the immunological markers of immature dendritic cells (iDCs), and this gene is located on chromosome 11 at 11q22.2. MMP12 is an elastolytic MMP and capable of degrading extracellular matrix components (Chelluboina et al., 2018). MMP12 plays a pivotal role in inflammatory diseases, such as colitis (Nighot et al., 2021) and chronic obstructive pulmonary disease (Baggio et al., 2020). In addition, MMP12 has been regarded as a potential prognostic biomarker for ovarian cancer (Guo et al., 2020) and gallbladder cancer (Zhao et al., 2019). Our results initially identified MMP12...
as a negative prognostic biomarker for UM. TIPARP is one of the immunological markers of eosinophils, and its gene is located on chromosome 3 at 3q25.31. TIPARP is a transcriptional repressor of aryl hydrocarbon receptor (AHR; MacPherson et al., 2013), which plays an important role in the immune system (Stevens et al., 2009). We firstly identified TIPARP as a favorable prognostic biomarker for the OS of UM. In line with our results, higher TIPARP expression has been reported to be related to better survival in breast cancer (Cheng et al., 2019). LRRN3 is one of the immunological markers of Th1 cells, and this gene is located on chromosome 7 at 7q31.1. Chou et al. (2013) found that reduced LRRN3 gene expression correlates with the senescent phenotype of CD8+ T cells. In neuroblastomas, low expression of LRRN3 is associated with a lower survival rate (Akter et al., 2011). In our study, LRRN3 is a negative prognostic biomarker for OS in UM.

Accumulating evidence shows that monosomy 3 and gain of chromosomal arm 8q are closely related to an increased risk of metastasis (Aalto et al., 2001; Trolet et al., 2009; Damato et al., 2010), while gain of chromosomal arm 6p and genetic alteration of SF3B1 correlate with longer MFS (Aalto et al., 2001; Yavuzyigitoglu et al., 2016). Consistent with the results of previous studies, the high-risk group characterized by the immunological marker-based prognostic model mainly had more epithelioid cell type, monosomy 3, 8q gains, but less 6p gains, and mutant in SF3B1. These clinical characteristics further prove that this immunological prognostic model could complement the molecular mechanism of UM.

It is well known that the eye is considered an immune privileged region (Forrester and Xu, 2012). There are many soluble immune suppressors in the aqueous humor, including transforming growth factor-beta (TGF-β), which plays an important role in the immune system (Forrester and Xu, 2012). There are many molecular mechanisms of UM. An immunological prognostic model could complement the SF3B1. These clinical characteristics further prove that this immunological prognostic model could complement the molecular mechanism of UM.

In this study, we developed a novel immunosignature constructed by MMP12, TIPARP, and LRRN3 that could effectively predict the OS of UM. In addition, our results suggested that eosinophils and Th17 cells may have a protective effect on the prognosis of UM, and calcium homeostasis may play an important role in immune infiltration. Future studies and clinical trials are warranted to further validate our findings.

DATA AVAILABILITY STATEMENT

RNA-seq data and corresponding clinical information were acquired from the TCGA database (https://portal.gdc.cancer.gov/projects/TCGA-UVM), the GSE44295 dataset (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44295), and the GSE22138 dataset (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22138) in the GEO.

AUTHOR CONTRIBUTIONS

CG: conceptualization, methodology, data curation, writing—original draft and review and editing, and visualization. XG: conceptualization, methodology, data curation, writing—original draft and review and editing. YW: conceptualization, software, formal analysis, writing—original draft, and visualization. ZY: conceptualization, writing—review and editing, visualization, supervision, and project administration. CZ: conceptualization,
ACKNOWLEDGMENTS

The authors would like to thank Yogen S from CleveLAND CLINIC LERNER COL/MED-CWRU (Cleveland, OH, United States) and Cecile Laurent from Institut Curie (Paris Cedex 05, France) for the public dataset of GSE44295 and GSE22138, respectively.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.710558/full#supplementary-material
Maat, W., van der Sliek, A. R., Verhoeven, D. H., Alizadeh, B. Z., Ly, L. V., Verduijn, W., et al. (2009). Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest. Ophthalmol. Vis. Sci. 50, 2888–2895. doi: 10.1167/iovs.08-2733

MacPherson, L., Tamblyn, L., Rajendra, S., Bralha, F., McPherson, J. P., and Matthews, J. (2013). 2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TIPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation. Nucleic Acids Res. 41, 1604–1621. doi: 10.1093/nar/gks1337

Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., et al. (2009). T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787–798. doi: 10.1016/j.immuni.2009.09.014

Nighot, M., Ganapathy, A. S., Saha, K., Suchanec, E., Castillo, E., Gregory, A., et al. (2021). Matrix Metalloproteinase MMP-12 promotes macrophage transmigration across intestinal epithelial tight junctions and increases severity of experimental colitis. J. Crohns. Colitis jjab664. doi: 10.1093/jcco/jjab664

Piaggio, F., Tozzo, V., Bernardi, C., Croce, M., Puzone, R., Viaggi, S., et al. (2019). Secondary somatic mutations in G-protein-related pathways and mutation signatures in uveal melanoma. Cancers (Basel) 11:1688. doi: 10.3390/cancers11111688

Quail, D. F., and Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437. doi: 10.1038/nm.3394

Rantala, E. S., Hernberg, M., and Kivelä, T. T. (2019). Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 29, 561–568. doi: 10.1097/cmr.0000000000000575

Shields, C. L., Kaliki, S., Shah, S. U., Luo, W., Furuta, M., and Shields, J. A. (2012). Iris melanoma: features and prognosis in 317 children and adults. J. AAPOS 16, 10–16. doi: 10.1016/j.jaapos.2011.10.012

Stevens, E. A., Mezrich, J. D., and Bradford, C. A. (2009). The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 127, 299–311. doi: 10.1111/j.1365-2567.2009.03054.x

Tian, Y., Han, C., Wei, Z., Dong, H., Shen, X., Cui, Y., et al. (2021). SOX5 activates a novel BORyt enhancer to facilitate experimental autoimmune encephalomyelitis by promoting Th17 cell differentiation. Nat. Commun. 12:481.

Trolet, J., Hupé, P., Huon, I., Lebigot, I., Decraene, C., Delattre, O., et al. (2009). Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest. Ophthalmol. Vis. Sci. 50, 2572–2580. doi: 10.1167/iovs.08-2296

Vander, M. C., Madigan, M. C., Versluis, M., Suleiman, H. M., Gezgin, G., Gruis, N. A., et al. (2017). GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br. J. Cancer 117, 884–887.

van Essen, T. H., van Pelt, S. I., Bronkhorst, I. H., Versluis, M., Némati, F., Laurent, C., et al. (2016). Upregulation of HLA expression in primary uveal melanoma by infiltrating leukocytes. PLoS One 11:e0164292.

Wang, B., Lindley, L. E., Fernandez-Vega, V., Rieger, M. E., Sims, A. H., and Briegg, K. J. (2012). The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells. PLoS One 7:e41355.

Wansleben, S., Davis, E., Peres, J., and Prince, S. (2013). A novel role for the anti-senesence factor TBX2 in DNA repair and cisplatin resistance. Cell Death Dis. 4:e846.

Whelchel, J. C., Farah, S. E., McLean, I. W., and Burnier, M. N. (1993). Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 34, 2603–2606.

Wilbanks, G. A., Mammolenti, M., and Streilein, J. W. (1992). Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur. J. Immunol. 22, 165–173. doi: 10.1002/eji.1830220125

Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., et al. (2013). Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961.

Yavuzyigitoglu, S., Koopmans, A. E., Verdijk, R. M., Vaarwater, J., Eussen, B., van Bodegom, A., et al. (2016). Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology 123, 1118–1128. doi: 10.1016/j.ophtha.2016.01.023

Zhao, X., Xu, M., Cai, Z., Yuan, W., Cui, W., and Li, M. D. (2019). Identification of LIFR, PIK3R1, and MMP12 as novel prognostic signatures in gallbladder cancer using network-based module analysis. Front. Oncol. 9:325.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.